Research Paper Volume 11, Issue 15 pp 5463—5482

Large-scale analysis reveals the specific clinical and immune features of CD155 in glioma

Fangkun Liu1,2, *, , Jing Huang3,4, *, , Yuanyuan Xiong1, , Shuwang Li1, , Zhixiong Liu1, ,

  • 1 Department of Neurosurgery, Xiangya Hospital, Central South University (CSU), Changsha 410008, China
  • 2 National Clinical Research Center for Geriatric Disorders,Xiangya Hospital, Central South University, Changsha, Hunan 410008, China
  • 3 Department of Psychiatry, the Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China
  • 4 Mental Health Institute of the Second Xiangya Hospital, Central South University, Chinese National Clinical Research Center on Mental Disorders (Xiangya), Chinese National Technology Institute on Mental Disorders, Hunan Key Laboratory of Psychiatry and Mental Health, Changsha, Hunan 410011, China
* Equal contribution

Received: April 21, 2019       Accepted: July 25, 2019       Published: August 4, 2019
How to Cite

Copyright © 2019 Liu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY) 3.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Recent studies demonstrated that CD155 plays an important role in anti-tumor immune responses. However, its role in glioma remains unclear. Here, we identify CD155 as a promising immune target in glioma. CD155 expression was significantly highly expressed in glioblastoma but not in normal brain tissue. Subsequent analysis based on genetic and clinical data from 1173 glioma patients in Rembrandt and TCGA dataset suggested that CD155 related genes of immune response were mainly positively correlated with CD155 expression. CD155 expression was positively correlated with immune-related metagenes STAT1, HCK, LCK, and MHC I but negatively associated with IgG. CD155 expression was positively correlated with biomarker gene expression of infiltrating immune cells, suggested that high CD155 expression in gliomas tend to have more infiltrating immune cells compared with gliomas with low CD155 expression. Pearson correlation analysis showed that CD155 is associated with CD96, CD226, Nectin4, PD-L1, B7-H2, NR2F6 and GITR, implying the potential synergistic effects of these checkpoint proteins. These findings implied that CD155 is a promising immunotherapy target, combined with existing immune checkpoint blockade therapies for glioma.


HGG: high-grade glioma; OS: Overall survival; PD-1: Programmed cell death protein 1; PD-L1: Programmed death ligand 1; CTLA-4: Cytotoxic T-lymphocyte-associated antigen-4; PVR: Poliovirus receptor; TIGIT: T-cell immunoglobulin and ITIM domain; GBM: Glioblastoma; Rembrandt: REpository for Molecular BRAin Neoplasia DaTa; TCGA: The Cancer Genome Atlas; ROC: Receiver operating characteristic; AUC: Area under the curve; BioPAX: the Biological Pathway Ex-change; GSVA: Gene set variation analysis; TAMs: Tumor-associated macrophages; NK: Natural killer; MDSCs: Myeloid-derived suppressor cells; DCs: Dendritic cells; Tregs: Regulatory T cells.